UniSuper Management Pty Ltd Buys 5,117 Shares of Stryker Co. (NYSE:SYK)

UniSuper Management Pty Ltd grew its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 31.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 21,501 shares of the medical technology company's stock after purchasing an additional 5,117 shares during the quarter. UniSuper Management Pty Ltd's holdings in Stryker were worth $7,741,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker during the fourth quarter worth about $25,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker during the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter valued at approximately $33,000. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Remove Ads

Stryker Stock Up 0.1 %

Shares of NYSE SYK traded up $0.28 during trading hours on Tuesday, hitting $372.53. The stock had a trading volume of 260,203 shares, compared to its average volume of 1,287,991. The firm's 50-day moving average price is $383.86 and its two-hundred day moving average price is $374.41. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a market capitalization of $142.19 billion, a P/E ratio of 47.86, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 earnings per share. Analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Citigroup restated a "buy" rating and set a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Finally, StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.